arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

Nasus Pharma Ltd

NSRX
$3.46 ▲ +0.29 (+9.34%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
4 Visible periods
5 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nasus Pharma Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share
Trailing P/E
Price / Book 11.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
27
Returns
2
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 4 quarters